Mellinghoff Ingo
机构: Memorial Sloan Kettering Cancer Center
每年引用次数
引用次数
引用: 35,177
H-指数: 75
I10-指数 : 150
出版物: 346
PL3.1 A phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent, IDH1-mutant, low-grade glioma: results from cohort 1
I K Mellinghoff , P Y Wen , J W Taylor , E A Maher
Neuro-oncology 21
13
2019
PATH-49. GENOMIC ATTRIBUTES OF TUMOR EVOLUTION AND TREATMENT RESPONSE IN DIFFUSE GLIOMA
A L Lin , P Jonsson , S Ogilvie , S Chavan
Neuro-oncology 20
2018
Identification of RAN binding protein 6 (RanBP6) as an EGFR feedback regulator and a tumor suppressor in glioblastoma.
W Hsieh , B Oldrini , H Erdjument-Bromage , P Codega
MOLECULAR BIOLOGY OF THE CELL 28
2017
Identification of RAN binding protein 6 as EGFR feedback regulator and candidate tumor suppressor.
W Hsieh , B Oldrini , H Erdjument-Bromage , P Codega
MOLECULAR BIOLOGY OF THE CELL 27
2016
18F-Fluoroglutamine PET as a Promising Prognostic Tool in IDH Mutant Glioma
S Krebs , MS Graham , M Grkovski , A Mauguen
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 48 ( SUPPL 1) S298 -S299
2021
A. 6 INDIGO: a global, randomized, double-blinded, Phase 3 study of vorasidenib versus placebo in patients with grade 2 glioma with an IDH1/2 mutation (mIDH1/2)
JR Perry , IK Mellinghoff , M van den Bent , DT Blumenthal
Canadian Journal of Neurological Sciences 51 ( s1) S4 -S4
2024
498O INDIGO: A randomized, double-blinded, phase III study of vorasidenib versus placebo in IDH1 or IDH2 low-grade glioma
D Blumenthal , IK Mellinghoff , MJ van den Bent , M Touat
Annals of Oncology 34 S391 -S391
2023
JOURNAL MEDICINE
IK Mellinghoff , MJ van den Bent , DT Blumenthal , M Touat
2023
Response of glioblastomas to EGFR kinase inhibitors-Reply
IK Mellinghoff , T Cloughesy , PS Mischel
NEW ENGLAND JOURNAL OF MEDICINE 354 ( 5) 526 -526
2006
OS1. 7 Genomic attributes of tumor evolution and treatment response in diffuse glioma
AL Lin , P Jonsson , S Ogilvie , S Chavan
Neuro-Oncology 20 ( Suppl 3) iii218 -iii218
2018
The inhibition of PI3K-Akt pathway enhances gamma-2 herpesvirus lytic replication and facilitates reactivation from latency
L Peng , TT Wu , JH Tchieu , J Feng
J Gen Virol 91 463 -469
4
2010
AKT activity determines sensitivity to mTOR inhibitors by regulating cycline D1 and c-myc expression.
JH Hsu , JF Gera , IK Mellinghoff , Y Shi
Journal of Biological Chemistry 2004 279 ( 4): 2737-2746 (sci)
1
2004
Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM).
AMP Omuro , K Beal , S Karimi , D Correa
Journal of Clinical Oncology 29 ( 15_suppl) 2028 -2028
9
2011
Investigating the role of CD79B in primary CNS lymphoma response to ibrutinib.
SS Tang , C Grommes , A Pastore , N Palaskas
MOLECULAR BIOLOGY OF THE CELL 28
2017
Combined inhibition of MAP kinase and KIT signaling effectively destabilizes the ETV1 protein and synergistically suppresses GIST tumorigenesis
L Ran , I Sirota , Z Cao , D Murphy
Cancer Discov 5 304 -315
4
2015
Identification of Ran Binding Protein 6 (RanBP6) as a Novel EGFR Regulator that is Frequently Silenced in Cancer.
W Hsieh , B Oldrini , H Erdument-Bromage , M Squatrito
MOLECULAR BIOLOGY OF THE CELL 26
2015
EGFRvIII, PTEN may determine response to EGFR inhibitors
IK Mellinghoff
Inpharma 1514 19 -19
2005
Differential sensitivity of glioma-versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2012; 2: 458–471. doi: 10.1158/2159-8290
I Vivanco , HI Robins , D Rohle , C Campos
CD-11-0284.[Europe PMC free article][Abstract][CrossRef][Google Scholar]
34
2012
Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. Sci Transl Med 7: 274ra17
S Venneti , MP Dunphy , H Zhang , KL Pitter
12
2015
Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov. 2017; 7: 1018–1029. doi: 10.1158/2159-8290
C Grommes , A Pastore , N Palaskas , SS Tang
CD-17-0613.[Europe PMC free article][Abstract][CrossRef][Google Scholar]
17